Home Featured Page 215

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

Psychedelic Research Bulletin: November 2021

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix...

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke...

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States...

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

Psychedelic Research Bulletin: November 2021

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix...

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke...

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States...

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY